that of all patients with IBD being dermatologically referred (n ¼ 251), 25% obtained the diagnosis of psoriasis (n ¼ 62). 7 Although limited data are available regarding the phenotype of patients with concomitant psoriasis and IBD, they might exhibit different characteristics compared with patients with one disease. 7 Knowledge about co-occurrence of PsA is hereby of importance, as psoriasis and PsA are closely related.
The coexistence of psoriasis, PsA, and IBD can potentially be explained by their common genetic background 8, 9 and similar pathogenic pathways. 1, 10 The current assumption is that psoriasis and/or IBD develop as a result of a combination of environmental and immunological factors in genetically susceptible individuals. An impaired interaction between the immune system 11, 12 and the microbiota contributes to IBD's etiology, 13 but also possibly to that of psoriasis. [14] [15] [16] Therapies for both diseases are overlapping, as immunosuppressants are the cornerstone of their treatment.
To be able to recognize the significance of the associations of these disorders, and to further explore their etiology, it is fundamental to expand the knowledge about the coexistent prevalence and shared features of these diseases. The aim of this study was to determine the prevalence of IBD and PsA in a psoriasis cohort. In addition, we investigated whether patients with both psoriasis and IBD carry a distinct phenotype compared with psoriasis-only and IBD-only patients.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.ibdjournal.org).
MATERIALS AND METHODS

Prevalence of IBD and PsA in a Psoriasis Cohort
To assess the prevalence of IBD in a psoriasis cohort, a retrospective chart review of outpatients was performed in a general hospital, Medical Center Leeuwarden (MCL), in the north of the Netherlands. MCL is one of the country's major topclinical centers, offering secondary and tertiary care. The institutional research board approved the protocol. All patients diagnosed with psoriasis by a dermatologist between January 1, 2009, and June 6, 2014, were included (n ¼ 1669). The patient records were screened for the comorbidities PsA and IBD. Diagnosis of psoriasis IBD and/or PsA was confirmed by the Dutch DBC system (diagnose-treatment combination), a detailed Dutch health care code which all physicians are required to generate, for health care insurance reimbursement purposes. 17 Furthermore, PsA diagnosis was only scored when made by a rheumatologist, whereas IBD diagnosis was confirmed by a gastroenterologist, based on endoscopy, as registered in the electronic patients' charts. Clinical characteristics were collected from the patients' medical charts; these data included visit reports, letters, and registrations from Departments of Dermatology, Rheumatology, and Gastroenterology and Hepatology. Characteristics that were retrieved were age at diagnosis of psoriasis, age at diagnosis of PsA, age at diagnosis of IBD, sex, smoking history, psoriasis type, psoriasis severity, medications, comorbidities, character, and location of CD and UC.
Phenotype of Patients with IBD and Psoriasis
To better investigate the phenotype of the psoriasis-IBD subgroup, we supplemented the psoriasis-IBD patients from the MCL (n ¼ 26), with 14 patients with both psoriasis and IBD from a biobank of the Erasmus Medical Center, Rotterdam, the Netherlands (EMC). These patients all signed written informed consent after the Medical Ethical Committee of the EMC approved the study. Again, the patients had a confirmed IBD diagnosis by a gastroenterologist based on endoscopy, a confirmed PsA diagnosis by a rheumatologist and a confirmed psoriasis diagnosis by a dermatologist.
The clinical features of patients with both IBD and psoriasis were assessed, and the analyses were performed separately for CD and UC, as well for IBD as a group.
Phenotype of Patients with Psoriasis and IBD Compared with Those with Only Psoriasis
To compare the phenotype of psoriasis-IBD patients to those with only psoriasis, we compared the features of psoriasis-IBD patients with psoriasis-only patients from the MCL cohort (n ¼ 1643). The following characteristics were compared between the groups: sex, age at onset of psoriasis, body mass index (BMI), medications, psoriasis type, psoriasis severity, and the presence of comorbidities.
Phenotype of Patients with Psoriasis and IBD Compared with Those with Only IBD
To compare the phenotype of psoriasis-IBD patients to IBD-only patients, we compared the features of psoriasis-IBD patients with IBD-only patients of the Delta Cohort, a populationbased inception cohort in the Netherlands. 18 In this cohort, psoriasis comorbidity was registered, which was excluded for this study (n ¼ 4). Patients with undifferentiated IBD (n ¼ 27) were also excluded, resulting in a total inclusion of 385 IBD-only patients. The following characteristics were compared between the groups: sex, age at onset of IBD, smoking history, BMI, medications, CD location, behavior, and UC location.
Statistical Analysis
The prevalence of IBD and PsA in a cohort of patients with psoriasis was calculated as the percentage of the total, with a confidence interval (CI). Data were expressed as median, range. The prevalence was compared with that of IBD in the Netherlands found in an earlier study. 5 Descriptive statistics, independent Mann-Whitney U tests, and x 2 tests were used. Missing data were excluded in the analysis. A 2-sided P-value of ,0.05 was considered statistically significant. Statistical analyses were performed with SPSS21 (IBM Corp., Armonk, NY).
RESULTS
The Prevalence of PsA in Psoriasis
PsA was diagnosed in 203 patients in a total of 1669 patients with psoriasis (12.2%, 95% CI, 10.5-13.7, see Supplementary Table 1 for characteristics, Supplemental Digital Content 1, http://links.lww.com/IBD/B533).
In patients with both psoriasis and PsA, the majority (n ¼ 141, 69.5%) was first diagnosed with psoriasis at median 37.7 years (interquartile range 26.1-50.3 years), followed by PsA at 45.2 years (36.4-57.2 years) with median 5.1 years between both diagnoses (0.9-11.7 years). In 24.1% (n ¼ 49) of patients, PsA was the first diagnosis at median 43.4 years (32.1-53.1 years) with psoriasis as second diagnosis at median 51.8 years (38.5-57.4 years) with median 3.0 years between both diagnoses (1.1-8.0 years). In 6.4% (n ¼ 13) of patients, they were diagnosed simultaneously at median 41.1 years (34.6-66.6 years).
The Prevalence of IBD in Psoriasis
Of all the 1669 patients with psoriasis, 26 were diagnosed with IBD (1.6%, 95% CI, 1.0-2.2), of which 12 (46.2%) had CD and 14 (53.8%) UC (see Supplementary Table 1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B533). With a prevalence of 1.6%, IBD was 4 times more common in psoriasis than in the general population in the Netherlands (0.4%). 5 Separate CD and UC analyses revealed that the CD prevalence in 1669 patients with psoriasis was 0.7% (95% CI, 0.4-1.3), whereas for UC, the prevalence was 0.8% (95% CI, 0.5-1.4).
In addition, the IBD prevalence was higher in patients suffering from both psoriasis and PsA (3.0%) compared with psoriasis-only patients (1.4%). Of the 6 patients suffering from all 3 diseases, 4 had CD and 2 UC.
Phenotype of Patients with Both Psoriasis and IBD Compared with Psoriasis-only
A total of 40 psoriasis-IBD patients were compared with 1643 psoriasis-only patients (Table 1) . For none of psoriasis-IBD patients, a conclusive trigger (such as anti-tumor necrosis factor alpha [TNF-a] treatment) was described for the development of psoriasis.
Sixty percent of psoriasis-IBD patients were women, versus 51.2% of psoriasis-only patients. BMI of psoriasis-only patients was comparable with that of psoriasis-IBD patients (26.8 versus 25.3). Psoriasis-IBD patients more often used anti-TNF-a therapy than psoriasis-only patients (P ¼ 0.025, 42.3% versus 21.9%). The same was observed for steroids (P , 0.001, 61.5% versus 2.3%), methotrexate (P ¼ 0.001, 46.2% versus 16.7%), and nonsteroidal anti-inflammatory drugs (P ¼ 0.006, 23.1% versus 6.4%). As expected, IBDspecific medications (azathioprine, mesalazine, sulfasalazine, and mercaptopurine) were significantly more frequently prescribed in psoriasis-IBD patients than in psoriasis-only patients (P , 0.001).
Psoriasis was diagnosed at a significant younger age in psoriasis-CD patients compared with psoriasis-only patients (P ¼ 0.001, 28.0 versus 43.5 yr). Most psoriasis-IBD patients had a mild psoriasis phenotype, similar to psoriasis-only patients (57.7% versus 58.0%). Plaque type was the most common subtype in both (65.0% versus 70.9%). Notably, psoriasis-UC patients had more psoriasis capitis than psoriasis-only patients (P ¼ 0.045). PsA frequency was significantly higher in psoriasis-IBD (22.5%), than in psoriasis-only (12.0%, P ¼ 0.045), and more often associated with psoriasis-CD (28.6%) than with psoriasis-UC (15.8%) patients. Furthermore, psoriasis-IBD patients had significantly more concomitant autoimmune diseases, other than PsA, than psoriasis-only patients (P ¼ 0.033, 10.0% versus 2.9%).
Phenotype of Patients with Both Psoriasis and IBD Compared with Only IBD
The characteristics of patients with both psoriasis and IBD (n ¼ 40) were compared with IBD-only patients (n ¼ 385, Table 2 ). In the psoriasis-IBD patients, 60% were women, versus 53% of IBD-only patients. Psoriasis-IBD patients had a comparable BMI (slightly higher) with IBD-only patients (25.3 versus 23.9). Of the psoriasis-IBD patients, 12.5% reported smoking, compared with 27.4% of IBD-only patients. Anti-TNF-a therapy was significantly more frequent prescribed in psoriasis-IBD patients than in IBD-only patients (P ¼ 0.023, 42.3% versus 21.0%). In addition, immunosuppressants were more often prescribed in psoriasis-IBD than in IBD-only patients (P , 0.001, 88.5% versus 42.1%). Mesalazine was less often prescribed in psoriasis-IBD compared with IBD-only patients (P , 0.001, 34.6% versus 84.4%).
CD was diagnosed in psoriasis at approximately the same frequency (52.5%) as UC (47.5%), a distribution that is comparable in IBD-only patients (51.7% CD and 48.3% UC). CD was diagnosed at a significant younger age in patients suffering from psoriasis than in CD-only patients (P ¼ 0.001, 20.0 versus 32.0 yr), which was not the case for UC (P ¼ 0.928). Indeed, at IBD diagnosis, psoriasis-CD patients were significantly younger than psoriasis-UC patients (P ¼ 0.001, 20.0 versus 41.0 yr, Table 2 ).
The CD location in psoriasis-CD patients was extensive in most patients (ileocolonic, 60.0%), compared with 40.1% of CDonly. Psoriasis-UC patients had extensive disease (pancolitis) in 33.3% compared with 18.9% of UC-only patients. Psoriasis-CD patients suffered significantly more often from perianal disease than CD-only patients (P ¼ 0.001). In addition, psoriasis-CD patients had significantly more often penetrating disease than CD-only patients (P , 0.001). A further division of the characteristics of the MCL (n ¼ 26 psoriasis-IBD patients) and EMC (n ¼ 14 psoriasis-IBD patients) cohorts was depicted in supplementary 
Phenotype of Patients with Psoriasis-CD Compared with Psoriasis-UC
At psoriasis diagnosis, psoriasis-CD patients were significantly younger than psoriasis-UC patients (P ¼ 0.014, 28.0 versus 46.0 yr, Table 1 ). Also, at IBD diagnosis, psoriasis-CD patients were significantly younger than psoriasis-UC patients (P ¼ 0.001, 20.0 versus 41.0 yr, Table 2 ).
Order of Diagnosis
The subsequent order of diagnosis of psoriasis-CD and psoriasis-UC patients is displayed in, respectively, Tables 3 and 4. CD was the first diagnosis in the majority of the psoriasis-CD patients (85.7%). Psoriasis-UC patients were almost as often first diagnosed with UC (52.6%) as with psoriasis (47.4%). The age at onset of patients first diagnosed with CD was median 20.0 years at CD diagnosis, whereas in UC, this was median 35.5 years. Moreover, the median time between first and second diagnosis when a patient was first diagnosed with UC was profoundly longer (16.7 yr) than with CD (7.4 yr). When psoriasis was diagnosed first, psoriasis-UC patients were older at psoriasis onset than psoriasis-CD patients (median 37.3 versus 25.8 yr).
DISCUSSION
In this study, the prevalence of IBD in psoriasis was 4 times higher than that in the general population. 5 Psoriasis-CD patients had an earlier disease onset of psoriasis and CD than patients with only psoriasis or CD. Psoriasis-PsA patients were more likely to develop IBD, especially CD, compared with psoriasis-only patients. In addition, psoriasis-IBD patients, in particular CD, were more likely to develop PsA than psoriasis-only patients. Besides PsA, other autoimmune diseases were also more frequently found in psoriasis-IBD patients than in psoriasis-only patients. The etiology of the association of psoriasis with IBD is unknown, and both diseases have similar treatments such as anti-TNF-a treatment. Interestingly, in clinical practice also paradoxical psoriasis induced by anti-TNF-a treatment has been observed; however, in our cohort, we did not observe such paradoxical psoriasis.
The prevalence of PsA in psoriasis in our cohort was 12.2%. Data of previous studies vary between 3% and 30%. [19] [20] [21] The prevalence of IBD in psoriasis patients in our cohort was 1.6%, which is higher than the 1.0% reported in a previous study, 6 and 4 times higher than in the prevalence reported in the general population (0.4%). Other studies have confirmed that patients with psoriasis are at increased risk for IBD 22 ; however, they showed no data about order of diagnosis and clinical characteristics of these patients. Our study showed that psoriasis-CD patients are most often diagnosed first with CD, whereas psoriasis-UC patients are as often first diagnosed with UC as psoriasis.
Whether psoriasis is more associated with CD or UC remains a debate. 6, 22, 23 In our psoriasis-IBD cohort, the ratio CD: UC was almost equal (1:1.07). However, for CD, more distinct characteristics of patients with both psoriasis and IBD were observed compared with patients with UC.
It can be hypothesized that the younger the age at onset, the more genetic factors contribute to the disease. Because psoriasis has a substantial overlap in genetic components with CD, 4, 8, 9 this might imply that genetic factors play a larger role in patients with both psoriasis and CD than in patients with 1 disease because psoriasis-CD patients were diagnosed at a significantly younger age with psoriasis and CD. This finding was not demonstrated in psoriasis-UC patients, potentially caused by a weaker genetic overlap. 6 It is known that UC has a higher age at onset than CD, 24, 25 which was confirmed by the cohorts in our study. Therefore in CD, a stronger genetic component might be involved, as studies of monozygotic twins demonstrated an estimated concordance rate of 50% in CD and 10% in UC. 26, 27 In addition, time between diagnoses was notably longer in psoriasis-UC patients first diagnosed with UC than that in psoriasis-CD patients (16.7 versus 7.4 yr). This was even more remarkable given the fact that psoriasis-IBD patients were already older when first diagnosed with UC than CD (35.5 versus 20.0 yr). Data on the phenotype of psoriasis-IBD patients are scarce, but one study of Lollie et al 7 found that psoriasis-IBD patients more often had mild psoriasis compared with psoriasis-only patients. Mild psoriasis was also most frequently seen in our psoriasis-IBD cohort, however not significantly different from the psoriasis-only patients. The difference might be explained by different methods, as Lolli et al included solely psoriasis-IBD patients first diagnosed with IBD, and thus patients with a higher age at psoriasis onset and possible another (even milder) phenotype. Nevertheless, the psoriasis phenotype was mild in both studies, which might be partially explained by the use of immunosuppressive medications for IBD, also effective for psoriasis. By contrast, a recent Danish study showed an increased risk for IBD in severe psoriasis. 23 However, in this study, severe psoriasis was classified as "psoriasis diagnosis made in the hospital by a dermatologist" which does not necessarily mark disease severity. The second classification for psoriasis severity used was "the use of systemic (specific) antipsoriatic therapy" thereby excluding the medication prescribed for both IBD and psoriasis, which might bias their results because they miss the strongest medications, and it is expected that psoriasis-IBD patients are prescribed medicaments effective for both IBD and psoriasis to treat 2 diseases at once.
In our psoriasis-CD cohort, the CD-phenotype was not mild, but severe. Patients with both diseases had significantly more penetrating and perianal disease than CD-only patients. Furthermore, although not significantly because of insufficient power, psoriasis-CD patients had more often an extensive disease location than CD-only patients. In addition, systemic medication such as steroids, and anti-TNF treatment were significantly more prescribed to psoriasis-IBD patients in comparison with IBD-only and psoriasis-only patients. This also seems to indicate more severe IBD and/or psoriasis in the psoriasis-IBD group, but it should be noted that this observation is difficult to interpret because of possible combined treatments of psoriasis and/or IBD. Together, these data suggest that a separate IBD entity exists with a more severe, earlier-onset CD-phenotype and concomitant immunological disorders such as, but not limited to, PsA and psoriasis (Tables 1 and 2) .
A confounder in these results could have been the shorter CD disease duration of the Delta Cohort (median 3.3 yr) compared with the psoriasis-CD cohort (median 13.0 yr). However, when comparing our results to other IBD cohorts in the literature with a longer CD disease duration, such as the IBDonly cohort of Lolli et al (median 10.0 yr), we still observe a more severe CD-phenotype of psoriasis-CD patients in our cohort compared with the CD-only patients described in these studies. Noticeably, the more severe CD course might be related to the younger age at onset in psoriasis-CD patients, as it is known that age at diagnosis is a contributing factor to CD severity. 28 The data collection from different cohorts is another limitation, although we did not observe profound differences between the EMC and MCL cohorts (see Supplementary  Table 2 , Supplemental Digital Content 2, http://links.lww. com/IBD/B534). We would propose a population-based study for future studies to confirm our results. While larger patient groups would be preferred to obtain a higher power, this study represents one of the largest psoriasis-IBD cohorts with phenotypic data in comparison with psoriasis-only and IBD-only patients so far. Furthermore, because of the retrospective nature, we anticipate that the prevalence in this study might be an underestimation of the true prevalence of IBD in psoriasis. It is conceivable that patients with mild IBD without a yet confirmed diagnosis were not registered in the patient charts and hence missed. It is plausible that IBD is more easily missed than psoriasis because of the ambiguous nature of symptoms and the common delay of IBD diagnosis. 29 Symptomatic psoriasis patients could be screened by endoscopy to investigate the presence of intestinal inflammation 30 and the potential presence of IBD; however, the invasive nature of endoscopies needs to be taken into account. Despite these potential pitfalls, the central position of the general hospital MCL in the northern part of the Netherlands allowed for inclusion of a broad range of patients for an accurate estimation of the prevalence, precluding tertiary center bias. Finally, this study emphasizes the increased prevalence of IBD in psoriasis, which confirms the need of awareness and recognition of IBD symptoms as comorbidity in psoriasis. Although psoriasis might be mild in patients with both diseases, they present a severe CD-phenotype and are diagnosed with psoriasis and CD at a younger age. Especially, patients with mild psoriasis and concomitant PsA are at risk for IBD, primarily CD. Furthermore, other autoimmune diseases are more often concurrent when a patient is already diagnosed with psoriasis and IBD. Thus, although physicians can expect that patients with concomitant psoriasis and IBD have a relatively mild psoriasis course, development of IBD warrants increased attention in these patients. An enhanced multidisciplinary approach between Departments of Dermatology, Gastroenterology, and Rheumatology, might lead to a more effective, therapeutic, and integrated approach for these patients.
